[
  {
    "ts": "2026-02-13T14:57:36+00:00",
    "headline": "Where is Regeneron Pharmaceuticals (REGN) Headed According to Analysts?",
    "summary": "Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the best medical research stocks to buy according to hedge funds. RBC Capital reiterated a Hold rating on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) on February 10, setting a price target of $745.00. In another development, Guggenheim lifted the price target on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) to $975 from $865 […]",
    "url": "https://finance.yahoo.com/news/where-regeneron-pharmaceuticals-regn-headed-145736538.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "8cd20ada-7200-3f51-a8ca-eb93ea0e61d0",
      "content": {
        "id": "8cd20ada-7200-3f51-a8ca-eb93ea0e61d0",
        "contentType": "STORY",
        "title": "Where is Regeneron Pharmaceuticals (REGN) Headed According to Analysts?",
        "description": "",
        "summary": "Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the best medical research stocks to buy according to hedge funds. RBC Capital reiterated a Hold rating on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) on February 10, setting a price target of $745.00. In another development, Guggenheim lifted the price target on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) to $975 from $865 […]",
        "pubDate": "2026-02-13T14:57:36Z",
        "displayTime": "2026-02-13T14:57:36Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/9b67531d4ce9e2fbb21fef60675f48d3",
          "originalWidth": 1456,
          "originalHeight": 816,
          "caption": "Regeneron (REGN) Draws Higher Target From TD Cowen",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/xYTEe3VE6sgZxe9COOwZXw--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/9b67531d4ce9e2fbb21fef60675f48d3.cf.webp",
              "width": 1456,
              "height": 816,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ku0XeMdDvNCP8FVlwzrrCw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/9b67531d4ce9e2fbb21fef60675f48d3.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/where-regeneron-pharmaceuticals-regn-headed-145736538.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/where-regeneron-pharmaceuticals-regn-headed-145736538.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "REGN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-13T15:23:00+00:00",
    "headline": "Ultragenyx Q4 Loss Wider Than Expected, Revenues Increase Y/Y",
    "summary": "RARE posts a wider-than-expected Q4 loss even as revenues jump 25% to $207 million, beating estimates. It also announces a strategic restructuring plan targeting profitability in 2027.",
    "url": "https://finance.yahoo.com/news/ultragenyx-q4-loss-wider-expected-152300619.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "2a6dea63-6baf-30c2-b7c9-a718b9d7cbc7",
      "content": {
        "id": "2a6dea63-6baf-30c2-b7c9-a718b9d7cbc7",
        "contentType": "STORY",
        "title": "Ultragenyx Q4 Loss Wider Than Expected, Revenues Increase Y/Y",
        "description": "",
        "summary": "RARE posts a wider-than-expected Q4 loss even as revenues jump 25% to $207 million, beating estimates. It also announces a strategic restructuring plan targeting profitability in 2027.",
        "pubDate": "2026-02-13T15:23:00Z",
        "displayTime": "2026-02-13T15:23:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/9c1d11cd27737fac4805145de6e5eee0",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/TNBAnrhWOnvvvNSvMEIuFg--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9c1d11cd27737fac4805145de6e5eee0.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/rP7ZEHNft_Sb_FB9M.3i3w--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9c1d11cd27737fac4805145de6e5eee0.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/ultragenyx-q4-loss-wider-expected-152300619.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/ultragenyx-q4-loss-wider-expected-152300619.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "RARE"
            },
            {
              "symbol": "ALKS"
            },
            {
              "symbol": "CSTL"
            },
            {
              "symbol": "REGN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-13T18:12:40+00:00",
    "headline": "Regeneron Allergy Antibodies And Dupixent Data Reframe Growth Prospects",
    "summary": "Regeneron Pharmaceuticals (NasdaqGS:REGN) is presenting Phase 3 data on first in class antibody therapies for cat and birch allergies at the AAAAI 2026 meeting. The company is also sharing new long term real world and clinical data for Dupixent across dermatological, respiratory, and gastrointestinal conditions, including in children. These updates highlight a potential new approach to allergen blocking along with broader evidence for Dupixent across multiple indications. Regeneron...",
    "url": "https://finance.yahoo.com/news/regeneron-allergy-antibodies-dupixent-data-181240421.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "0749e51d-2c72-3986-99fc-738fc01fa004",
      "content": {
        "id": "0749e51d-2c72-3986-99fc-738fc01fa004",
        "contentType": "STORY",
        "title": "Regeneron Allergy Antibodies And Dupixent Data Reframe Growth Prospects",
        "description": "",
        "summary": "Regeneron Pharmaceuticals (NasdaqGS:REGN) is presenting Phase 3 data on first in class antibody therapies for cat and birch allergies at the AAAAI 2026 meeting. The company is also sharing new long term real world and clinical data for Dupixent across dermatological, respiratory, and gastrointestinal conditions, including in children. These updates highlight a potential new approach to allergen blocking along with broader evidence for Dupixent across multiple indications. Regeneron...",
        "pubDate": "2026-02-13T18:12:40Z",
        "displayTime": "2026-02-13T18:12:40Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/a52f4d4b48157c0b8b51190845e3ba14",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/w30LARiR1Z35GusfaFi.2g--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/a52f4d4b48157c0b8b51190845e3ba14.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/3eDp_RSETU8kXm3usDK_gQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/a52f4d4b48157c0b8b51190845e3ba14.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/regeneron-allergy-antibodies-dupixent-data-181240421.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/regeneron-allergy-antibodies-dupixent-data-181240421.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "REGN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-13T04:39:29+00:00",
    "headline": "1 Healthcare Stock Worth Your Attention and 2 Facing Challenges",
    "summary": "Personal health and wellness is one of the many secular tailwinds for healthcare companies. Players catalyzing medical advancements have benefited from elevated demand, and their momentum is only rising as the industry has posted a 9.3% gain over the past six months, beating the S&P 500 by 2 percentage points.",
    "url": "https://finance.yahoo.com/news/1-healthcare-stock-worth-attention-043929680.html",
    "source": "StockStory",
    "provider": "yfinance",
    "raw": {
      "id": "e10ec0bc-ee25-352f-abad-a8324fd8467b",
      "content": {
        "id": "e10ec0bc-ee25-352f-abad-a8324fd8467b",
        "contentType": "STORY",
        "title": "1 Healthcare Stock Worth Your Attention and 2 Facing Challenges",
        "description": "",
        "summary": "Personal health and wellness is one of the many secular tailwinds for healthcare companies. Players catalyzing medical advancements have benefited from elevated demand, and their momentum is only rising as the industry has posted a 9.3% gain over the past six months, beating the S&P 500 by 2 percentage points.",
        "pubDate": "2026-02-13T04:39:29Z",
        "displayTime": "2026-02-13T04:39:29Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/stockstory_922/863b7649ab1334021118a8518d7e40cd",
          "originalWidth": 1400,
          "originalHeight": 700,
          "caption": "REGN Cover Image",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/E5YeVaDzgHlFxvDwMx9gpg--~B/aD03MDA7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/stockstory_922/863b7649ab1334021118a8518d7e40cd.cf.webp",
              "width": 1400,
              "height": 700,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/6HLp77Q1Eazwpb8zaGf6Xg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/stockstory_922/863b7649ab1334021118a8518d7e40cd.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "StockStory",
          "url": "https://stockstory.org/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/1-healthcare-stock-worth-attention-043929680.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/1-healthcare-stock-worth-attention-043929680.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "REGN"
            },
            {
              "symbol": "ILMN"
            },
            {
              "symbol": "MOH"
            },
            {
              "symbol": "^GSPC"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]